›1.independentA method of reducing the frequency of tumor initiating cells in a subject comprising administering to the subject an anti-DLL3 antibody drug conjugate…+26

›2.↳ 1The method of claim 1, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:nM comprises an anti-DLL3 antibody;L comprise…d2+11

›3.↳ 2The method of claim 2, wherein M comprises an anti-DLL3 antibody that specifically binds to an epitope within the DSL domain of a DLL3 protein set for…d3

›4.↳ 2The method of claim 2, wherein the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205 and P206 (SEQ ID NO: 10).d3

›5.↳ 2The method of claim 2, wherein the anti-DLL3 antibody is an internalizing antibody.d3

›6.↳ 2The method of claim 2, wherein the anti-DLL3 antibody is a chimeric antibody, a CDR-grafted antibody, or a humanized antibody.d3

›7.↳ 2The method of claim 2, wherein the anti-DLL3 antibody competes for binding to human DLL3 protein with an antibody comprising a light chain variable re…d3

›8.↳ 2The method of claim 2, wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2…d3

›9.↳ 2The method of claim 2, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO…d3

›10.↳ 2The method of claim 2, wherein the pyrrolobenzodiazepine (PBD) comprises the formula AC:d3+3

›14.↳ 1The method of claim 1, wherein the tumor initiating cells are lung cancer cells.d2

›15.↳ 1The method of claim 1, wherein the lung cancer cells are small cell lung cancer cells.d2

›16.↳ 1The method of claim 1, wherein the reduction in frequency is determined using flow cytometric analysis of tumor cell surface markers known to enrich f…d2

›17.↳ 1The method of claim 1, wherein the reduction in frequency is determined using in vitro or in vivo limiting dilution analysis.d2+1

›19.↳ 1The method of claim 1, wherein the frequency of tumor initiating cells is reduced by at least 10%.d2

›20.↳ 1The method of claim 1, wherein the frequency of tumor initiating cells is reduced by at least 90%.d2

›21.↳ 1The method of claim 1, wherein the frequency of tumor initiating cells is reduced by at least 100-fold.d2

›22.↳ 1The method of claim 1, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof wherein…d2+5

›28.independentA method of reducing the frequency of tumor initiating cells in a subject, the method comprising administering to the subject an anti-DLL3 antibody dr…

›29.independentA method of reducing the frequency of tumor initiating cells in a subject, the method comprising administering to the subject an anti-DLL3 antibody dr…

›30.independentA method of reducing the frequency of tumor initiating cells in a subject, the method comprising administering to the subject an anti-DLL3 antibody dr…

Classifications

16 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395
A61K31/5517
A61K47/48
A61K39/00

Section C — Chemistry; metallurgy

C07K16/28
C07K16/30
C07K16/00
C07K16/18

Section G — Physics

G01N33/574

USPC · US Patent Classification

424/134.1424/141.1530/388.1424/130.1530/387.1530/387.9424/139.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

0.7 y

242 days filing → grant

Office actions

none on record

Responses

1 RCE

Examiner

Christine J Saoud

art unit 1647 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 195 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

29 Oct 2012

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61719803	29 Oct 2012
related publication	US 20140363455 A1	11 Dec 2014

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.